

Adaptive Semi-Supervised Inference for Optimal Treatment Decisions with Electronic Medical Record Data

Kevin Gunn, Wenbin Lu*, and Rui Song

Department of Statistics, North Carolina State University, Raleigh 27607, North Carolina, U.S.A.

**email*: wlu4@ncsu.edu

SUMMARY: A treatment decision is a rule that assigns a treatment to a patient based on their observed clinical information. The treatment decision that yields the greatest overall expected clinical benefit to the entire patient population is called the optimal treatment decision. We consider estimation of the optimal treatment decision within the restricted class of linear decision rules under semi-supervised settings, where the data consists of a set of ‘labeled’ patients and a much larger set of ‘unlabeled’ patients. This paper proposes an imputation-based semi-supervised method, SSQ-SNP, utilizing ‘unlabeled’ individuals into the linear decision rule to offer a more efficient estimator. An inference procedure and results for asymptotic normality and consistency are provided. We present simulation studies to assess its performance relative to a fully supervised method and the effects of misspecification for the proposed linear decision rule. Afterward, application to an EMR study on the treatment of hypotensive episodes during an ICU stay is discussed.

KEY WORDS: Optimal treatment decision; Inverse probability weighting; Q -learning; Personalized medicine; Potential outcomes; Propensity score; Semi-supervised learning; Kernel regression; Electronic medical records; MIMIC-III.

1. Introduction

Precision medicine, which is focused on creating treatment decisions for a patient based on his/her clinical information, has earned considerable interest. A treatment decision is a rule which, given a patient's observed clinical information, assigns a treatment to the patient. The objective is to choose the treatment, from the set of all possible treatments, that maximizes the patient's expected outcome. This creates a treatment tailored to each patient in the population of interest. The treatment decision that yields the greatest overall expected clinical benefit to the entire patient population is called the optimal treatment decision (OTD).

A recent area of interest in optimal treatment decision estimation has been the utilization of Electronic Medical Record (EMR) data. These data allow researchers to explore optimal treatment decisions in specific clinical scenarios not feasible in a randomized clinical trial (RCT) such as patients suffering from sepsis (Raghu et al., 2017). EMR data can also provide guidance where there is little previous research conducted, including second line treatment choices for type 2 diabetes episodes (Wang et al., 2016). The recent shift in hospitals and other healthcare organizations to store clinical information in EMRs has an immense amount of detailed information on the clinical process of patients and their health status during interactions with their healthcare system. With databases such as MIMIC-III, an openly available critical care data set (Johnson et al., 2016), these data are more readily accessible. MIMIC-III encompasses medical record chart data recorded by clinicians such as; demographics, medical diagnoses, medications, vital signs, laboratory measurements (obtained in and out of the hospital), progress notes, imaging results, and billing information. The wealth of detailed clinical data provides the opportunity to enhance clinical decisions for accurate personalized medicine.

There is a great deal of work on statistical techniques to estimate the OTD from RCT data

or observational study data under fully supervised settings, where a single decision or a series of sequential decisions may be of interest (Murphy, 2003; Moodie et al., 2007; Robins, 2004; Zhao et al., 2012; Zhang et al., 2012). The purpose of this paper is to address the estimation of the OTD under an assumed linear *working* model, where the majority of individuals are missing response or treatment information. In other words, a semi-supervised learning (SSL) problem. In SSL, the knowledge gained through $\mathbb{P}_{\mathbf{X}}$ (distribution of \mathbf{X}) from the ‘unlabeled’ individuals is incorporated to improve inference on $\mathbb{P}_{\mathbf{Y}|\mathbf{X}}$ (Chapelle et al., 2006). In the OTD setting, we extend this to include treatment information, \mathbf{A} , into the inference procedure by trying to estimate $\mathbb{P}_{\mathbf{Y}|\mathbf{X},\mathbf{A}}$ using $\mathbb{P}_{\mathbf{A}|\mathbf{X}}$ and $\mathbb{P}_{\mathbf{X}}$. The proposed semi-supervised (SS) method is a three-step semi-parametric estimator to find the target parameter, β , from the assumed linear *working* model. We combine SSL with Q -learning (Schulte et al., 2014; Nahum-Shani et al., 2012) to estimate the OTD at one decision point. Q -learning posits a model, denoted as the Q -function, for the outcome of interest given the subject’s information for each available treatment. The OTD finds the treatment that maximizes the Q -function. The proposed method is an imputation based semi-nonparametric kernel regression Q -function (SSQ-SNP) that is flexible to the underlying distribution, $\mathbb{P}_{\mathbf{Y}|\mathbf{A},\mathbf{X}}$. This is necessary when the assumed *working* model is misspecified. The ‘unlabeled’ subjects have their outcome imputed for each treatment, followed by a linear regression of the imputed contrast between against the covariates to obtain the OTD. SSQ-SNP’s incorporation of all available data into the estimation procedure for the OTD intends to reduce the bias and the standard error for the parameters of interest.

Our work also discusses a fully supervised linear estimator, titled the transformed response ordinary least squares (TR-OLS), to estimate the OTD. TR-OLS combines inverse propensity score weighted estimators with a linear model to estimate β . The focus with both approaches is on providing linear decision rules in low-dimensional settings due to their simple interpre-

tations. Our method, SSQ-SNP, is intended to be adaptive to the true underlying distribution making it robust to model misspecification, and the TR-OLS estimator measures the benefit of including the covariate information from the ‘unlabeled’ subjects into the estimation procedure.

This article is organized as follows; Section 2 discusses the assumptions and framework for optimal treatment decisions. The estimation procedure and asymptotic theory results are presented in Section 3 for TR-OLS and Section 4 for SSQ-SNP, respectively. Section 5 provides simulation studies to compare the empirical performances of both methods. Section 6 demonstrates an application to a study of patients in the ICU undergoing a hypotensive episode. Afterward, a discussion about future work within the area of optimal treatment decision estimation with EMR data is given.

2. Framework and Assumptions

Treatments received by patients will be denoted $A \in \mathcal{A}$, where \mathcal{A} is the set of possible treatments. Let $\mathbf{X} \in \mathcal{X} \subseteq \mathbb{R}^p$ be a vector of subject characteristics ascertained prior to treatment. We will further assume \mathcal{X} is a compact set, and $Var(\mathbf{X})$ is positive definite. Let $Y \in \mathbb{R}$ denote the observed response variable of interest and consider a larger value of Y as the better outcome. Suppose we have a fully ‘observed’ subject group, $\mathbf{O} = [\mathbf{O}_i = \{Y_i, A_i, \mathbf{X}_i\} : i = 1, \dots, n \text{ are i.i.d.}]$, and an ‘unobserved’ subject group where the treatment and/or response are not available, $\mathbf{U} = [\mathbf{X}_j : j = n + 1, \dots, N \text{ are i.i.d.}]$, where $N \gg n$. Assume \mathcal{O} has finite 2^{nd} moments and all observations, $\mathcal{O} \cup \mathcal{L}$, are drawn from the same underlying distribution, $\mathbb{P} = (\mathbb{P}_{Y|A, \mathbf{X}}, \mathbb{P}_{A|\mathbf{X}}, \mathbb{P}_{\mathbf{X}})$, i.e. the response and treatment information is missing completely at random (MCAR). The mathematical formulation of the optimal treatment decision will be defined to clarify the estimation procedure.

Consider a disease with two treatment options, each patient is assigned one treatment and the patient’s response to that treatment is observed, but it is unknown how the patient would

respond to the other choice of treatment. This motivates the concept of *potential* responses to treatment. The *potential* response based on each treatment is the response value that would be observed if a patient were given treatment 1 or 0, respectively. It will be denoted as $Y^*(1)$ and $Y^*(0)$. Assume the patient's response to the given treatment is constructed as, $Y_i = A_i Y^*(1) + (1 - A_i) Y^*(0)$ (Rubin, 1978). This assumption is referred to as the *consistency* assumption, which states the observed response is equal to the potential response under the treatment actually received by the patient. Furthermore, it is assumed that there are *no unmeasured confounders*, i.e., $(Y^*(1), Y^*(0)) \perp A \mid \mathbf{X}$ (Rosenbaum and Rubin, 1983). The last assumption made is the *positivity* assumption, which states, the probability of receiving a treatment $a \in \mathcal{A}$ is greater than zero. Let $\pi(\mathbf{X})$ denote the propensity score, i.e. $\pi(\mathbf{X}) = P(A = 1 \mid \mathbf{X})$. It holds that $0 < \pi(\mathbf{X}) < 1$ by the *positivity* assumption.

Formally, a treatment decision is a rule that maps the covariates onto the treatment space, $\delta : \mathcal{X} \rightarrow \mathcal{A}$. A decision rule is implemented as a treatment, $Y^*(\delta) = \delta(\mathbf{X})Y^*(1) + (1 - \delta(\mathbf{X}))Y^*(0)$. The optimal treatment decision is denoted as δ^{opt} , and is defined as $\delta^{opt} = \arg \max_{\delta \in \Delta} E[Y^*(\delta)]$, where Δ is the class of all treatment decisions. Under this framework, $E[Y^*(\delta)] = E_{\mathbf{X}} \{ \delta(\mathbf{X})E[Y \mid \mathbf{X}, A = 1] + (1 - \delta(\mathbf{X}))E[Y \mid \mathbf{X}, A = 0] \}$. Hence, the OTD becomes, $\delta^{opt} = I(E[Y \mid \mathbf{X}, A = 1] - E[Y \mid \mathbf{X}, A = 0] \geq 0)$.

Suppose the following model for the rest of the article, $E[Y \mid \mathbf{X}, A] = \mu(\mathbf{X}) + AC(\mathbf{X})$. The function, $\mu(\mathbf{X})$, represents the baseline effects of \mathbf{X} on Y , and the contrast function, $C(\mathbf{X}) = E[Y \mid \mathbf{X}, A = 1] - E[Y \mid \mathbf{X}, A = 0]$, is the expected difference between treatments on the individual given his/her covariates. We further consider a linear contrast function as our assumed *working* model, i.e. $E[Y \mid \mathbf{X}, A] = \mu(\mathbf{X}) + A(\boldsymbol{\beta}'\tilde{\mathbf{X}})$, where $\tilde{\mathbf{X}} = (1, \mathbf{X}')'$. The OTD, δ^{opt} , arising from a posited linear model with parameter, $\boldsymbol{\beta}$, will belong to the class of estimators, $\Delta_{\boldsymbol{\beta}}$, and be denoted as $\delta_{\boldsymbol{\beta}}^{opt}$. Our estimator for the OTD within $\Delta_{\boldsymbol{\beta}}$ can be deduced to the function, $\hat{\delta}_{\boldsymbol{\beta}}^{opt}(\mathbf{X}) = I(\hat{\boldsymbol{\beta}}'\tilde{\mathbf{X}} > 0)$, where $\hat{\boldsymbol{\beta}}$ is the solution to the normal equations.

This class of estimators is chosen to produce decision rules that are easily interpretable due to their simplicity.

3. Transformed Response Ordinary Least Squares

The OTD is a function of $C(\mathbf{X})$, and as a result it is not necessary to estimate the baseline effect, $\mu(\mathbf{X})$. To reduce the possibility of model misspecification, we estimate δ_{β}^{opt} without fully specifying $E[Y | \mathbf{X}, A = a]$ for $a \in \{0, 1\}$. The transformed response ordinary least squares (TR-OLS) method regresses $C(\mathbf{X})$ directly onto the covariates to provide a fully supervised linear decision rule for the OTD.

TR-OLS uses an inverse propensity weighted (IPW) estimator of $C(\mathbf{X})$ as responses in a linear model. An unbiased IPW estimator for $C(\mathbf{X})$ is,

$$\tilde{Y} = \frac{Y(A - \pi(\mathbf{X}))}{\pi(\mathbf{X})(1 - \pi(\mathbf{X}))}.$$

Therefore, the transformed response model is, $\tilde{Y} = C(\mathbf{X}) + \epsilon$, whereby under the assumed *working* model $C(\mathbf{X})$ is equivalent to $\beta' \tilde{\mathbf{X}}$ and $E[\epsilon | \mathbf{X}] = 0$. The least squares is minimized to obtain $\hat{\beta}_{TR}$, the regression parameters for the observed cases,

$$\hat{\beta}_{TR} = \arg \min_{\beta} \sum_{i=1}^n [\tilde{Y}_i - \beta' \tilde{\mathbf{X}}_i]^2. \quad (1)$$

Under the assumptions given in section 2 and as $n \rightarrow \infty$,

$$\sqrt{n}(\hat{\beta}_{TR} - \beta) = n^{-1/2} \sum_{i=1}^n \Psi_{TR}(\mathbf{O}_i) + o_p(1) \xrightarrow{d} N_{p+1}(0, V_{\beta_{TR}}), \quad (2)$$

where $\Psi_{TR}(\mathbf{O}) = \Lambda^{-1} \tilde{\mathbf{X}} (\tilde{Y} - \beta'_{TR} \tilde{\mathbf{X}})$ and $\Lambda = E[\tilde{\mathbf{X}} \tilde{\mathbf{X}}']$. The asymptotic variance, $V_{\beta_{TR}}$, is equivalent to $E[\Psi_{TR}(\mathbf{O}) \Psi'_{TR}(\mathbf{O})]$. Consistent estimators for $V_{\beta_{TR}}$ and Λ are given by $\hat{V}_{\beta_{TR}} = \frac{1}{n} \sum_{i=1}^n \Psi_{TR}(\mathbf{O}_i) \Psi'_{TR}(\mathbf{O}_i)$ and $\Lambda_n = n^{-1} \sum_{i=1}^n \tilde{\mathbf{X}}_i \tilde{\mathbf{X}}'_i$, respectively.

The supervised estimator, $\hat{\beta}_{TR}$, uses data only from \mathcal{O} . By including the data from \mathcal{U} , the SS estimator intends to create a more efficient estimator for β relative to $\hat{\beta}_{TR}$. The parameter, $\hat{\beta}_{TR}$, gauges the improvement offered by incorporating \mathcal{U} into the estimation procedure discussed in Sections 4.1 and 4.2. An increase in efficiency for the linear decision

rule employed in the OTD is the primary goal, especially under model misspecification, as it signifies a more robust estimator for $\widehat{\delta}_{\beta}^{opt}$. A discussion of Q -learning for a single decision point is needed to establish the difference in the SS approach.

4. Semi-Supervised Q-Learning for a Single Decision Point

Q -learning at a single decision point aims to estimate the expected outcome of interest conditioned on treatment and covariates, $Q(\mathbf{x}, a) = E[Y | \mathbf{X} = \mathbf{x}, A = a]$. Q -functions typically model $Q(\mathbf{x}, a)$ using all the observed data, \mathcal{O} , with a parametric or semi-parametric estimator, $Q(\mathbf{x}, a, \boldsymbol{\theta})$, where $\boldsymbol{\theta}$ is a finite-dimensional parameter. Estimators for $\boldsymbol{\theta}$ are obtained through the proper estimating equations for the linear or non-linear models posited for $Q(\mathbf{x}, a)$ (Schulte et al., 2014). Using the estimator, $Q(\mathbf{x}, a, \boldsymbol{\theta})$, the OTD is defined as $I(Q(\mathbf{x}, 1, \boldsymbol{\theta}) - Q(\mathbf{x}, 0, \boldsymbol{\theta}) \geq 0)$. Given the assumed *working* model, the Q -functions are expressed as, $Q(\mathbf{x}, a) = \mu(\mathbf{x}) + a(\boldsymbol{\beta}'\tilde{\mathbf{x}})$, and the OTD is equivalent to $\delta_{\beta}^{opt}(\mathbf{x}) = I(\boldsymbol{\beta}'\tilde{\mathbf{x}} \geq 0)$. If the data available consists of sets \mathcal{O} and \mathcal{U} , then Q -functions should use all available data to make treatment decisions. We propose a three-step SS imputation procedure as follows: (i) impute $Q(\mathbf{X}_j, a)$ for $a \in \{0, 1\}$ and $\forall j = n + 1, \dots, N$, (ii) compute the imputed contrast functions, $C(\mathbf{X}_j) = Q(\mathbf{X}_j, 1) - Q(\mathbf{X}_j, 0)$ for $\forall j = n + 1, \dots, N$, (iii) regress the imputed contrast functions on \mathbf{X} to obtain $\widehat{\beta}$ for δ_{β}^{opt} .

4.1 Fully Nonparametric Imputation of the Q -Function

If all the Y and A in \mathcal{U} were actually observed, we could obtain an estimate for β utilizing the entire data set with the TR-OLS approach discussed in Section 3. Instead, we must use a different approach. We present a fully non-parametric estimator based on kernel regression (KR). KR is a locally weighted average function with no parametric assumptions. The kernel function is denoted as $W(\cdot)$ with $W : \mathbb{R}^p \rightarrow \mathbb{R}$. The bandwidth, h , is a function of n and greater than zero. In practice, h is often estimated using \mathcal{K} -fold cross validation. Q -functions

as KR estimators are defined as,

$$Q^{(np)}(\mathbf{x}, 1) = \frac{\sum_{i=1}^n W\left(\frac{\mathbf{x} - \mathbf{X}_i}{h}\right) A_i Y_i}{\sum_{i=1}^n W\left(\frac{\mathbf{x} - \mathbf{X}_i}{h}\right) A_i} \quad (3)$$

and,

$$Q^{(np)}(\mathbf{x}, 0) = \frac{\sum_{i=1}^n W\left(\frac{\mathbf{x} - \mathbf{X}_i}{h}\right) (1 - A_i) Y_i}{\sum_{i=1}^n W\left(\frac{\mathbf{x} - \mathbf{X}_i}{h}\right) (1 - A_i)}. \quad (4)$$

The first step is to impute both $Q^{(np)}(\mathbf{x}, 0)$ and $Q^{(np)}(\mathbf{x}, 1)$, followed by the computation of $\widehat{C}^{(np)}(\mathbf{x})$. The set \mathcal{U} with imputed data is $\left\{ \widehat{C}^{(np)}(\mathbf{X}_j), \mathbf{X}_j \right\} : j = n + 1, \dots, N$, and the solution the normal equations is obtained by minimizing the argument,

$$\widehat{\beta}_{np} = \arg \min_{\beta} \sum_{j=n+1}^N \left[\widehat{C}^{(np)}(\mathbf{X}_j) - \beta' \widetilde{\mathbf{X}}_j \right]^2. \quad (5)$$

The new nonparametric SS linear decision rule is $\widehat{\delta}_{\beta_{np}}^{opt} = I(\beta'_{np} \widetilde{\mathbf{X}} > 0)$, and utilizes $\mathbb{P}_{\mathbf{X}}$ from \mathcal{U} .

The subsequent assumptions are needed for Theorem 1 given below. Most of these assumptions are fairly standard (Fan, 1992; Hansen, 2008; Newey, 1994), but are adapted slightly to the framework needed for OTDs. (1) $h \equiv h(n) = o(1)$, (2) $Q^{(np)}(\mathbf{x}, a)$, $\pi(\mathbf{x})$, and $f(\cdot)$ are r times continuously differentiable with bounded r^{th} derivatives on some open set within \mathcal{X} . (3) $W(\cdot)$ is a symmetric r^{th} order kernel for some integer $r \geq 2$. $W(\cdot)$ is Lipschitz continuous and has bounded support that it shares with $\pi(\cdot)$, $\mathcal{W} \subseteq \mathbb{R}^p$. (4) $E(|AY|^s) < \infty$ and $E(|(1-A)Y|^s) < \infty$ for some $s > 2$. (5) $E(|AY|^s | \mathbf{X} = \mathbf{x})f(\mathbf{x}) = E(|Y|^s | \mathbf{X} = \mathbf{x})\pi(\mathbf{x})f(\mathbf{x})$ and $f(\mathbf{x})$ are bounded on \mathcal{X} and $\inf_{\mathbf{x} \in \mathcal{X}} f(\mathbf{x}) > 0$.

THEOREM 1: Suppose $n^{1/2}h^r \rightarrow 0$ and $\sqrt{\frac{\ln n}{nh^p}} \rightarrow 0$ as $n \rightarrow \infty$ and $N \gg n$ such that $n/N \rightarrow 0$. Then, under the required assumptions (1)-(5),

$$n^{1/2} \left(\widehat{\beta}_{np} - \beta \right) = n^{-1/2} \sum_{i=1}^n \Psi_{np}(\mathbf{O}_i) + o_p(1) \xrightarrow{d} N_{p+1} \left(0, V_{\beta_{np}} \right)$$

where $\Psi_{np}(\mathbf{O}) = \left\{ \frac{A}{\pi(\mathbf{X})} - \frac{1-A}{1-\pi(\mathbf{X})} \right\} \Lambda^{-1} \mathbf{X} (Y - Q^{(np)}(\mathbf{X}, A))$ and asymptotic variance, $V_{\beta_{np}} = E \left[\Psi_{np}(\mathbf{O}) \Psi'_{np}(\mathbf{O}) \right]$.

There are drawbacks to using KR owing to the *curse of dimensionality* and inherent *finite*

sample bias. Fan (1992) discusses *finite sample bias* for KR has order of h^2 for 2^{nd} order kernels, and through Taylor expansion it is clear the bias has order of h^r for r^{th} order kernels. For this article, the goal is developing an efficient low-dimensional linear decision rule, so the *curse of dimensionality* is not of concern. However, if the sample size within \mathcal{O} is not large enough, β_{np} is a biased estimator. In Section 4.2, we discuss a cross-validation technique to correct for bias with a linear term by regressing the residuals, $Y - Q^{(np)}(\mathbf{x}, a)$, against the covariates.

4.2 Semi-Nonparametric Imputation of the Q-Function

We overcome the issue of *finite sample bias* in nonparametric estimation by adapting the work of Chakraborty and Cai (2018) on semi-nonparametric imputation based estimators into the SS OTD framework. The new semi-nonparametric (SSQ-SNP) estimator, $Q^{(SS)}(\mathbf{x}, a, \theta_a)$, builds upon the estimator in Section 4.1, but produces a more efficient estimator for β by reducing bias. SSQ-SNP achieves this through a *linear refitting* step.

SSQ-SNP is composed of two steps, where the first step is to fit the KR estimator, $\hat{Q}^{(np)}(\mathbf{x}, a)$, on the data in \mathcal{O} , and the second step (*linear refitting* step) corrects for the bias of $\hat{Q}^{(np)}(\mathbf{x}, a)$ with a linear model. The *linear refitting* step applies an inverse propensity score weighted least squares regression of the residuals, $Y - Q^{(np)}(\mathbf{X}, a)$, on \mathbf{X} to obtain estimates for the parameters of interest, θ_a for $a \in \{0, 1\}$. Namely, θ_a for $a \in \{0, 1\}$, are the solutions to minimizing the weighted least squares equations,

$$\hat{\theta}_1 = \arg \min_{\theta_1} \sum_{k=1}^{\mathcal{K}} \sum_{i \in \mathcal{O}_k} \frac{A_i}{\pi(\mathbf{X}_i)} \left(Y_i - \hat{Q}_k^{(np)}(\mathbf{X}_i, A_i) - \theta_1' \tilde{\mathbf{X}}_i \right)^2 \quad (6)$$

and,

$$\hat{\theta}_0 = \arg \min_{\theta_0} \sum_{k=1}^{\mathcal{K}} \sum_{i \in \mathcal{O}_k} \frac{1 - A_i}{1 - \pi(\mathbf{X}_i)} \left(Y_i - \hat{Q}_k^{(np)}(\mathbf{X}_i, A_i) - \theta_0' \tilde{\mathbf{X}}_i \right)^2. \quad (7)$$

The *linear refitting* step utilizes \mathcal{K} -fold cross-validation to obtain an unbiased estimator of θ_a for $a \in \{0, 1\}$. Cross-validation separates \mathcal{O} into \mathcal{K} partitions of equal size, where

both treatment cohorts have their populations split equally among the folds. The partitions are denoted as \mathcal{O}_k for $k \in \{1, 2, \dots, \mathcal{K}\}$. Cross-validation overcomes underestimation of the true residuals caused by over-fitting during the kernel regression step. The final imputation function is $Q^{(SS)}(\mathbf{x}, a, \boldsymbol{\theta}_a) = Q^{(np)}(\mathbf{x}, a) + \boldsymbol{\theta}'_a \mathbf{x}$, which is estimated as:

$$\widehat{Q}^{(SS)}(\mathbf{x}, a, \widehat{\boldsymbol{\theta}}_a) = \frac{1}{\mathcal{K}} \sum_{k=1}^{\mathcal{K}} \widehat{Q}_k^{(np)}(\mathbf{x}, a) + \widehat{\boldsymbol{\theta}}'_a \widetilde{\mathbf{x}}, \quad (8)$$

for $a \in \{0, 1\}$. We compute $\widehat{C}^{(SS)}(\mathbf{x}) = \widehat{Q}^{(SS)}(\mathbf{x}, 1, \widehat{\boldsymbol{\theta}}_1) - \widehat{Q}^{(SS)}(\mathbf{x}, 0, \widehat{\boldsymbol{\theta}}_0)$, and obtain $\widehat{\boldsymbol{\beta}}_{SS}$ similarly to Equation 5. The OTD based on SSQ-SNP is $\widehat{\delta}_{\boldsymbol{\beta}_{SS}}^{opt} = I(\widehat{\boldsymbol{\beta}}'_{SS} \widetilde{\mathbf{x}} > 0)$.

We need an additional condition for the influence function given in Theorem 2 to be unbiased and consistent: *condition (1)* let $\widehat{\mathbf{R}}_{k,a}(\mathbf{X}) = \mathbf{X}[\widehat{Q}_k^{(np)}(\mathbf{X}, a) - Q^{(np)}(\mathbf{X}, a)]$ and $\bar{\mathbf{R}}_{k,a}(\mathbf{X}) = E[\widehat{\mathbf{R}}_{k,a}] - \widehat{\mathbf{R}}_{k,a}$, $\mathcal{R}_{n,\mathcal{K},a} = n^{-1/2} \sum_{k=1}^{\mathcal{K}} \sum_{i \in \mathcal{O}_k} \bar{\mathbf{R}}_{k,a}(\mathbf{X}_i)$. Then for $\mathcal{K} \geq 2$, $\mathcal{R}_{n,\mathcal{K},a} = o_p(1)$, $\forall a \in \mathcal{A}$ by Lemma A.1 in Chakraborty and Cai (2018).

THEOREM 2: Suppose the KR estimator, $Q^{(np)}(\mathbf{X}, a)$, satisfies assumptions (1) through (5) and condition (1) holds,

$$n^{1/2} (\widehat{\boldsymbol{\beta}}_{SS} - \boldsymbol{\beta}) = n^{-1/2} \sum_{i=1}^n \Psi_{SS}(\mathbf{O}_i) + o_p(1) \xrightarrow{d} N_{p+1}(0, V_{\boldsymbol{\beta}_{SS}})$$

where $\Psi_{SS}(\mathbf{O}) = \left\{ \frac{A}{\pi(\mathbf{X})} - \frac{1-A}{1-\pi(\mathbf{X})} \right\} \Lambda^{-1} \mathbf{X} (Y - Q^{(SS)}(\mathbf{X}, A, \boldsymbol{\theta}_A))$ and asymptotic variance, $V_{\boldsymbol{\beta}_{SS}} = E[\Psi_{SS}(\mathbf{O}) \Psi'_{SS}(\mathbf{O})]$.

See Web Appendix for proofs for Theorem 1 and 2.

Both SSQ-SNP and TR-OLS incorporate propensity scores into their estimation procedure, but SSQ-SNP is much less reliant on correct specification of the propensity score in situations where it needs to be estimated. The function, $Q^{(np)}(\mathbf{X}, a)$, avoids specification of $\pi(\mathbf{X})$. If $\pi(\mathbf{X})$ must be estimated, the *linear refitting* step utilizes a separate estimator of $\pi(\mathbf{X})$, such as a logistic regression model. The *linear refitting* step increases the variance of $\boldsymbol{\beta}_{SS}$ with respect to $\boldsymbol{\beta}_{np}$, but substantially reduces bias in its estimation of $\boldsymbol{\beta}$. SSQ-SNP is an adaptive

imputation estimator since it does not assume a fully parametric model for $Q(\mathbf{x}, a)$, which allows flexibility during the imputation procedure of \mathcal{U} .

4.3 Inference for Semi-Supervised Q -Functions

The SSQ-SNP Q -functions, $Q^{(SS)}(\mathbf{x}, a, \hat{\boldsymbol{\theta}}_a)$, over-fit Y in \mathcal{O} due to the *linear refitting* step. Due to this issue, $\hat{V}_{\beta_{SS}} = n^{-1} \sum_{i=1}^n \Psi_{SS}(\mathbf{O}_i) \Psi'_{SS}(\mathbf{O}_i)$ underestimates $V_{\beta_{SS}}$ in practice. A ‘double-CV’ step is proposed to reduce bias during the variance estimation procedure (Chakraborty and Cai, 2018). We create \mathcal{K} folds, \mathcal{O}_k for $k \in \{1, \dots, \mathcal{K}\}$, then construct \mathcal{K} distinct estimates of $\boldsymbol{\theta}_a$, $\{\boldsymbol{\theta}_{a,(k)} : k = 1, \dots, \mathcal{K}\}$. Let \mathcal{O}_k^* represent the data not included in \mathcal{O}_k , where $\mathcal{O}_k^* \perp \mathcal{O}_k$ and $\mathcal{O}_k^* \cup \mathcal{O}_k = \mathcal{O}$. Fold \mathcal{O}_k is not involved in estimating $\left\{ \hat{Q}^{(np)}(\mathbf{X}_i, A_i) \right\}_{i \in \mathcal{O}_k^*}$ as well as the parameter, $\boldsymbol{\theta}_{a,(k)}$, to mirror imputation of missing response information in the SS setting. The cross-validated estimate $\boldsymbol{\theta}_{a,(k)}$ is the solution to:

$$\hat{\boldsymbol{\theta}}_{1,(k)} = \arg \min_{\boldsymbol{\theta}_1} \sum_{i \notin \mathcal{O}_k} \frac{A_i}{\pi(\mathbf{X}_i)} \left(Y_i - \hat{Q}_k^{(np)}(\mathbf{X}_i, A_i) - \boldsymbol{\theta}_1' \mathbf{X}_i \right)^2 \quad (9)$$

$\forall k \in \{1, \dots, \mathcal{K}\}$, where $\boldsymbol{\theta}_{0,(k)}$ is estimated analogously. The ‘double-CV’ imputation function becomes, $\hat{Q}_k^{(SS)}(\mathbf{x}, a, \boldsymbol{\theta}_{a,(k)}) = \hat{Q}_k^{(np)}(\mathbf{x}, a) + \hat{\boldsymbol{\theta}}_{a,(k)}' \mathbf{x}$. We substitute $\hat{Q}_k^{(SS)}(\mathbf{x}, a, \boldsymbol{\theta}_{a,(k)})$ for $\hat{Q}^{(SS)}(\mathbf{x}, a, \boldsymbol{\theta}_a)$ in the corresponding influence functions from Theorem 2. The estimators $\Lambda_N = N^{-1} \sum_{j=n+1}^N \tilde{\mathbf{X}}_j \tilde{\mathbf{X}}_j'$ and Λ_{n+N} are consistent estimators of Λ that use the available data in \mathcal{U} . The asymptotic variance, $V_{\beta_{SS}}$, has the consistent ‘double-CV’ estimator:

$$\hat{V}_{\beta_{SS,(\mathcal{K})}} = \frac{1}{n} \sum_{i=1}^n \Psi_{SS,(k)}(\mathbf{O}_i) \Psi'_{SS,(k)}(\mathbf{O}_i), \quad (10)$$

which allows us to establish standard error and confidence intervals estimates for $\hat{\beta}_{SS}$.

5. Simulation Analysis

This simulation study examines the performance of SSQ-SNP and TR-OLS at estimating the OTD. We present the percent of correct decisions (PCD) and value function to illustrate the benefits of semi-supervised prediction on assessing δ_{β}^{opt} . Furthermore, we study the bias,

empirical standard error (ESE), asymptotic standard error (ASE), and the relative efficiency of $\widehat{\beta}_{SS}$ with respect to $\widehat{\beta}_{TR}$.

5.1 Data Generation

In this simulation, n is the amount of subjects in \mathcal{O} and N is the amount of subjects in \mathcal{U} . The N unobserved responses were simulated to be missing completely at random (MCAR), where the response and treatment are not observed. Let $\mathbf{X} \sim N(\mathbf{0}_p, I_p)$, where \mathbf{X} is contained in $[-5, 5]^p$ to ensure it is in a compact set, and $\mathcal{A} \in \{0, 1\}$. The following models are tested with $p = 2$, $n = 500$ and $N = 5000$,

- *Model 1 (Linear)*: $\mathbf{Y} = \mu(\mathbf{X}) + \mathbf{A}(\boldsymbol{\eta}'\mathbf{X}) + \epsilon$
- *Model 2 (Cubic)*: $\mathbf{Y} = \mu(\mathbf{X}) + \mathbf{A}(\boldsymbol{\gamma}'\mathbf{X})^3 + \epsilon$
- *Model 3 (Sine)*: $\mathbf{Y} = \mu(\mathbf{X}) + \mathbf{A}(\sin(\boldsymbol{\eta}'\mathbf{X})) + \epsilon$,

where $\boldsymbol{\eta} = \mathbf{1}_2$, $\boldsymbol{\gamma} = (0.3, 0.6)'$, and $\epsilon \sim \mathcal{N}(0, 1)$. Two baseline functions were studied. The first one simulates a situation where the baseline effect for subjects is small and the second function proposes a larger baseline effect,

- (1) $\mu(\mathbf{X}) = (\boldsymbol{\alpha}'\mathbf{X})(1 + \boldsymbol{\omega}'\mathbf{X})$,
- (2) $\mu(\mathbf{X}) = (\boldsymbol{\omega}'\mathbf{X})^3$.

The models were studied with $\boldsymbol{\omega} = (0.5, 0.5)'$ and $\boldsymbol{\alpha} = (0.75, 0.75)'$. We simulate a propensity score of $\pi(\mathbf{X}) = \text{logit}(0.5X_1 - 0.5X_2)$, and an allocation of treatment as $\mathbf{A} \sim \text{bernoulli}(p = \pi(\mathbf{X}))$. The propensity scores were generated to simulate observational data where the allocation of treatment depends on a patient's health status information. The true values, β_0 , are estimated by simulating a fully observed Monte Carlo data set of size 500,000.

5.2 Simulation Results

The results of interest are percent of correct decisions (PCD), value function (V), and component-wise relative efficiency (RE) over 500 replications. The component-wise RE for each estimator was calculated as $\sum_{i=1}^{500} \|\hat{\beta}_{TR-OLS,i,j} - \beta_{0,j}\|^2 / \sum_{k=1}^{500} \|\hat{\beta}_{SSQ-SNP,j} - \beta_{0,j}\|^2$, where $j = 1, \dots, p+1$. During each replication, new vectors \mathbf{Y} , \mathbf{A} and matrix \mathbf{X} are simulated. The percent of correct decisions (PCD) was calculated for each method,

$$PCD_i = 1 - \frac{1}{5500} \sum_{k=1}^{5500} \left| I(\hat{\beta}' \mathbf{X}_k > 0) - I(\beta_0' \mathbf{X}_k > 0) \right|,$$

and then averaged over all 500 simulations, $PCD = (1/500) \sum_{i=1}^{500} PCD_i$. The true value function is calculated with the Monte Carlo data set of sample size 500,000 as,

$$V_0 = \frac{1}{500,000} \sum_{m=1}^{500,000} \{ \mu(\mathbf{X}_m) + I(C(\mathbf{X}_m) > 0) C(\mathbf{X}_m) \}.$$

Estimation of the value function using TR-OLS or SSQ-SNP is calculated as,

$$\hat{V}_i = \frac{1}{500,000} \sum_{m=1}^{500,000} \left\{ \mu(\mathbf{X}_m) + \hat{\delta}_{\beta}^{opt} C(\mathbf{X}_m) \right\},$$

on the same Monte Carlo data set and then averaged over 500 replications. Since we assume a larger response to treatment is preferred, a larger value function signifies an OTD that on average provides the best treatment allocation to the population of interest. A Gaussian kernel was chosen for $W(\cdot)$, and a value of $\mathcal{K} = 5$ was chosen for cross-validation.

Table 1 summarizes the value function and PCD results under all 6 settings. SSQ-SNP outperforms TR-OLS in every setting according to both value function and PCD results. Inclusion of ‘unlabeled’ subjects and less reliance on $\pi(\mathbf{X})$ make SSQ-SNP a robust estimator for β .

[Table 1 about here.]

Table 2 presents the bias, empirical SE, asymptotic SE, component-wise RE, and component-wise coverage probabilities of the 95% confidence intervals for SSQ-SNP and TR-OLS under both settings for $\mu(\mathbf{X})$. SSQ-SNP demonstrates its ability to reduce SE of

the parameters in the linear model regardless of the true underlying model. This translates to a more precise estimator for δ_{β}^{opt} .

[Table 2 about here.]

The OTD estimator, $\hat{\delta}_{\beta_{SS}}^{opt}$, obtained through SSQ-SNP is particularly advantageous when model misspecification occurs according to Table 1. The results suggest $\hat{\delta}_{\beta_{SS}}^{opt}$ is the preferred estimator for δ_{β}^{opt} , especially under varying degrees of model misspecification for the assumed *working* model.

6. Application to an EMR Study

We apply our proposed method, SSQ-SNP, to an EMR study on patients undergoing a hypotensive episode in the ICU within the MIMIC-III database. It is important to treat hypotensive episodes (HE's) in ICU patients to minimize end-organ damage. A marker of end-organ damage is an increase in serum creatinine, post-hypotensive episode (Lehman et al., 2010). An initial serum creatinine measurement is taken no earlier than 24 hours before the start of the episode. Subsequently, a post-episode serum creatinine measurement is performed no more than 72 hours after the HE. The two available treatments for HE's include IV fluid resuscitation and vasopressors. Our objective is to determine the optimal treatment between IV fluid resuscitation and vasopressor interventions to minimize the increase in serum creatinine post-hypotensive episode for each patient.

Our study cohort is defined similarly to Lee et al. (2012). The beginning of an HE is defined as the time of two successive mean arterial pressure (MAP) measurement values $> 60 \text{ mm Hg}$, followed by two MAP measurements $\leq 60 \text{ mm Hg}$. The end of an HE is defined as the time that two successive MAP measurements $\leq 60 \text{ mm Hg}$, followed by two successive MAP measurements $> 60 \text{ mm Hg}$ is observed (Lee et al., 2012).

To formulate this problem into the OTD framework, we must define Y as the negative of the

difference between pre-HE and post-HE serum creatinine measurements. The treatment space is defined as $A = 1$ if the patient was given vasopressor treatment, or $A = 0$ if they received IV fluid resuscitation. Vasopressor treatments include dobutamine, dopamine, epinephrine, norepinephrine, phenylephrine, milrinone or vasopressin during the HE. IV fluid treatment is defined as receiving at least one infusion of colloids or isotonic crystalloid of at least 250 ml. The predictors, \mathbf{X} , include normalized versions of baseline serum creatinine measurement prior to and within 24 hours of the HE and age of the subject. Patients receiving medical and surgical services during their ICU stay were included in the study, which provided a total of 3,316 individuals. The number of patients with treatment and response available amounted to 1,243 and the number of patients missing treatment and/or response information was 2,073. For this data analysis, we are focusing on the semi-supervised setting, therefore we randomly choose $n = 300$ out of 1,243 subjects to create the fully observed set, \mathcal{O} .

Recall SSL relies on the assumption all individuals are drawn from \mathbb{P} , which means the distribution for each of the predictors should come from $\mathbb{P}_{\mathbf{X}}$ regardless of set, \mathcal{O} or \mathcal{U} , the individual belongs in. Table 3 provides tests for equality between the distributions of \mathbf{X} between the two data sets.

[Table 3 about here.]

Propensity scores were modeled with a logistic regression model that included the following covariates; baseline creatinine, age, gender, service type (medical or surgical), total urine output, mean blood oxygen saturation, and average mean arterial pressure. The last three covariates use recorded information from the 4 hours prior to the HE. We perform TR-OLS and SSQ-SNP on the data set. A Gaussian kernel was chosen for $W(\cdot)$ in Equations 3 and 4 and $\mathcal{K} = 5$ similar to Section 5. Table 4 presents the point estimates, estimated SE, and p-values for testing null effects. SSQ-SNP reduces the estimated ASE for each predictor.

[Table 4 about here.]

In Table 5, we demonstrate treatment allocation given by both methods on all subjects in the data set. The OTD's estimated by SSQ-SNP and TR-OLS produce similar treatment decisions for the vast majority of subjects. SSQ-SNP assigns more patients to a vasopressor treatment than TR-OLS and is less likely to assign IV fluid resuscitation. The point estimates are relatively close, but the smaller ASE for SSQ-SNP suggests it is the more reliable estimator.

[Table 5 about here.]

7. Discussion

We proposed a new method for estimating the optimal treatment decision within a specified class of rules at a single decision point, where the class is chosen based on considerations of simplicity and interpretation. Extensive simulation shows the proposed method, SSQ-SNP, outperforms a supervised regression method under the correct specification and misspecification of the assumed *working* model. An application to an EMR study illustrates SSQ-SNP improvements in efficiency of the linear regression coefficients involved in the optimal treatment decision.

This method does have limitations. It is not designed directly for high dimensional data as the *curse of dimensionality* is a problem with kernel regression estimators. Dimension reduction techniques, such as principal component analysis or sliced inverse regression, can be utilized to reduce information provided by all the covariates into a lower-dimensional subspace for accurate prediction with kernel regression estimators, but this eliminates the ability to make simple interpretations from the decision rules created by SSQ-SNP. An appropriate incorporation of high-dimensional data is necessary to fully utilize the available information from EMR studies. This work may be extended to create dynamic optimal

treatment regimes utilizing Electronic Health Record data that has information on patients with extended periods of stay or multiple visits to the ICU.

8. Supplementary Materials

Web Appendix referenced in Section 4.2 is available with this paper at the *Biometrics* website on Wiley Online Library. R code implementing SSQ-SNP is available with this paper at the *Biometrics* website on Wiley Online Library as well.

ACKNOWLEDGEMENTS

.

REFERENCES

- Chakraborty, A. and Cai, T. (2018). Efficient and adaptive linear regression in semi-supervised settings. *The Annals of Statistics* **46**, 1541–1572.
- Chapelle, O., Scholkopf, B., and Zien, A. (2006). *Semi-Supervised Learning*. MIT Press, Cambridge, MA, USA.
- Fan, J. (1992). Design-adaptive nonparametric regression. *Journal of the American statistical Association* **87**, 998–1004.
- Hansen, B. E. (2008). Uniform convergence rates for kernel estimation with dependent data. *Econometric Theory* **24**, 726–748.
- Johnson, A. E. et al. (2016). Mimic-iii, a freely accessible critical care database. *Scientific data* **3**, 160035.
- Lee, J., Kothari, R., Ladapo, J. A., Scott, D. J., and Celi, L. A. (2012). Interrogating a clinical database to study treatment of hypotension in the critically ill. *BMJ open* **2**, e000916.

- Lehman, L.-w., Saeed, M., Moody, G., and Mark, R. (2010). Hypotension as a risk factor for acute kidney injury in icu patients. *Computing in cardiology* **37**, 1095.
- Moodie, E. E., Richardson, T. S., and Stephens, D. A. (2007). Demystifying optimal dynamic treatment regimes. *Biometrics* **63**, 447–455.
- Murphy, S. A. (2003). Optimal dynamic treatment regimes. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* **65**, 331–355.
- Nahum-Shani, I., Qian, M., Almirall, D., Pelham, W. E., Gnagy, B., Fabiano, G. A., Waxmonsky, J. G., Yu, J., and Murphy, S. A. (2012). Q-learning: A data analysis method for constructing adaptive interventions. *Psychological Methods* **17**, 478.
- Newey, W. K. (1994). Kernel estimation of partial means and a general variance estimator. *Econometric Theory* **10**, 1–21.
- Raghu, A., Komorowski, M., Celi, L. A., Szolovits, P., and Ghassemi, M. (2017). Continuous state-space models for optimal sepsis treatment-a deep reinforcement learning approach. *arXiv preprint arXiv:1705.08422* .
- Robins, J. M. (2004). Optimal Structural Nested Models for Optimal Sequential Decisions. In Lin, D. Y. and Heagerty, P. J., editors, *Proceedings of the Second Seattle Symposium in Biostatistics*. New York: Springer.
- Rosenbaum, P. R. and Rubin, D. B. (1983). The central role of the propensity score in observational studies for causal effects. *Biometrika* **70**, 41–55.
- Rubin, D. B. (1978). Bayesian inference for causal effects: The role of randomization. *The Annals of Statistics* **6**, 34–58.
- Schulte, P., Tsiatis, A., Laber, E., and Davidian, M. (2014). Q-and A-learning methods for estimating optimal dynamic treatment regimes. *Statistical Science: a Review Journal of the Institute of Mathematical Statistics* **29**, 640–661.
- Wang, Y., Wu, P., Liu, Y., Weng, C., and Zeng, D. (2016). Learning optimal individualized

treatment rules from electronic health record data. *2016 IEEE International Conference on Healthcare Informatics (ICHI)* pages 65–71.

Zhang, B., Tsiatis, A. A., Laber, E. B., and Davidian, M. (2012). A robust method for estimating optimal treatment regimes. *Biometrics* **68**, 1010–1018.

Zhao, Y., Zeng, D., Rush, A. J., and Kosorok, M. R. (2012). Estimating individualized treatment rules using outcome weighted learning. *Journal of the American Statistical Association* **107**, 1106–1118.

Received October 2007. Revised February 2008. Accepted March 2008.

Table 1

Average PCD and Average Value Function over 500 replications for $\hat{\delta}_{\beta_{TR}}^{opt}$ and $\hat{\delta}_{\beta_{SS}}^{opt}$. Empirical SEs are provided in parentheses.

$\mu(\mathbf{X})$	Model	V_0	TR-OLS		SSQ-SNP	
			V	PCD	V	PCD
$(\omega' \mathbf{X})^3$	Linear	0.56	0.54 (0.04)	0.92 (0.06)	0.56 (0.01)	0.96 (0.02)
	Cubic	0.24	0.22 (0.06)	0.87 (0.12)	0.24 (0.01)	0.93 (0.05)
	Sine	0.32	0.21 (0.12)	0.80 (0.17)	0.26 (0.06)	0.88 (0.09)
$(\alpha' \mathbf{X})(1 + \omega' \mathbf{X})$	Linear	1.31	1.29 (0.05)	0.91 (0.06)	1.31 (0.01)	0.96 (0.02)
	Cubic	0.99	0.98 (0.05)	0.86 (0.11)	0.99 (<0.01)	0.94 (0.04)
	Sine	1.06	0.96 (0.11)	0.80 (0.16)	1.02 (0.04)	0.89 (0.06)

Table 2
Component-wise Bias, Empirical SE, Asymptotic SE, Coverage Probability (CP) for 95% CI, and RE under both baseline effects.

(a) $\mu(\mathbf{X}) = (\boldsymbol{\omega}'\mathbf{X})^3$										
Model	β	TR-OLS				SSQ-SNP				
		Bias	ESE	ASE	CP	Bias	ESE	ASE	CP	RE
Linear	0	-0.010	0.220	0.209	0.94	-0.005	0.123	0.122	0.95	3.21
	1	-0.021	0.329	0.347	0.98	-0.008	0.182	0.173	0.93	3.28
	1	-0.020	0.355	0.347	0.97	-0.004	0.198	0.175	0.92	3.22
Cubic	0	-0.008	0.206	0.205	0.94	0.001	0.123	0.132	0.95	2.80
	0.41	0.002	0.352	0.338	0.95	-0.002	0.212	0.193	0.95	2.74
	0.81	0.002	0.423	0.390	0.94	-0.010	0.239	0.212	0.91	3.14
Sine	0	-0.006	0.171	0.168	0.96	0.004	0.118	0.116	0.95	2.13
	0.37	-0.007	0.282	0.270	0.94	-0.011	0.170	0.158	0.91	2.74
	0.37	0.011	0.296	0.272	0.94	0.011	0.176	0.161	0.92	2.82

(b) $\mu(\mathbf{X}) = (\boldsymbol{\alpha}'\mathbf{X})(1 + \boldsymbol{\omega}'\mathbf{X})$										
Model	β	TR-OLS				SSQ-SNP				
		Bias	ESE	ASE	CP	Bias	ESE	ASE	CP	RE
Linear	0	-0.017	0.242	0.230	0.94	-0.007	0.114	0.116	0.95	4.53
	1	-0.012	0.348	0.326	0.94	0.011	0.150	0.151	0.93	5.37
	1	-0.021	0.352	0.347	0.94	-0.011	0.163	0.154	0.91	4.66
Cubic	0	-0.005	0.236	0.223	0.93	-0.026	0.121	0.122	0.95	3.77
	0.41	-0.014	0.341	0.313	0.93	0.003	0.155	0.154	0.92	4.86
	0.81	-0.004	0.432	0.392	0.91	-0.008	0.193	0.186	0.92	4.99
Sine	0	0.003	0.210	0.202	0.94	0.009	0.117	0.113	0.95	3.14
	0.37	0.002	0.296	0.289	0.94	-0.004	0.146	0.146	0.94	4.12
	0.37	-0.005	0.300	0.290	0.93	0.001	0.136	0.140	0.95	4.90

Table 3

Mean and SD of Fully Observed (\mathcal{O}) and Unlabeled (\mathcal{U}) data before scaling. Wilcoxon Rank Sum Tests and Kolmogorov–Smirnov test to compare both data sets.

	\mathcal{O}		\mathcal{U}		P-values from Diagnostic Tests	
Predictors	Mean	SD	Mean	SD	Wilcoxon Test	KS Test
Baseline Creatinine	1.52	1.40	1.44	1.25	0.97	0.49
Age	67.6	13.5	67.6	12.9	0.74	0.88

Table 4*Estimated regression coefficients and ASE. P-values for testing $H_0 : \beta_{TR} = 0$ and $\beta_{SS} = 0$.*

Predictors	TR-OLS			SSQ-SNP		
	β_{TR}	ASE	P-Value	β_{SS}	ASE	P-Value
Intercept	-0.102	0.111	0.355	-0.119	0.102	0.246
Baseline Creatinine	-0.371	0.256	0.147	-0.508	0.197	0.010
Age	0.196	0.146	0.178	0.114	0.133	0.392

Table 5
Treatment allocation given by SSQ-SNP and TR-OLS.

		SSQ-SNP	
		Treatment IV Fluid	Vasopressors
TR-OLS	IV Fluid	1553	314
	Vasopressors	119	1330